Ma, Liangsuo http://orcid.org/0000-0002-8856-098X
Cunningham, Kathryn A. http://orcid.org/0000-0002-4257-1739
Anastasio, Noelle C. http://orcid.org/0000-0001-5579-4213
Bjork, James M. http://orcid.org/0000-0003-0593-3291
Taylor, Brian A.
Arias, Albert J.
Riley, Brien P. http://orcid.org/0000-0002-2408-8268
Snyder, Andrew D.
Moeller, F. Gerard
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (P50 DA033935, U54 DA038999)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
Article History
Received: 2 June 2021
Revised: 10 April 2022
Accepted: 12 April 2022
First Online: 6 May 2022
Competing interests
: FGM has past research funding from Indivior Pharmaceuticals and Nektar Therapeutics for research unrelated to this study. KAC and NCA have current research funding from VidaLibreBio, Inc., for research unrelated to this study. Other authors declare no competing interests.